Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial save search
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
IGXT | $0.1851 -19.77% 71K
|
Manufacturing
|
| O: -5.24%
H: 8.65%
C: 8.65%
versafilm first disease montelukast parkinson’s trial
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CORT M | $23.17 -1.45% -1.47% 720K
|
Health Technology
|
| O: 2.41%
H: 0.0%
C: -4.98%
cancer trial
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.32 -1.49% -1.52% 37K
|
Professional, Scientific, and T...
|
| O: -1.5%
H: 0.0%
C: -2.29%
brtx-100 disease trial
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
INZY | $4.71 -8.37% -9.13% 740K
|
Health Technology
|
| O: 2.2%
H: 7.69%
C: -9.69%
inz-701 pharma positive ongoing trials topline
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Published: 2024-04-08 (Crawled : 11:00) - prnewswire.com
SNDX | $21.61 -0.51% -0.51% 1M
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -1.34%
gment-101 positive leukemia trial
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
OCGN | $1.585 -7.31% -7.89% 6.9M
|
Health Technology
|
| O: 26.42%
H: 3.48%
C: -6.47%
ocu400 fda first clearance trial therapy
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS 3 d | $12.01 0.46% 0.46% 20K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
REPL | $7.13 -0.14% -0.14% 670K
|
Health Technology
|
| O: 3.27%
H: 0.13%
C: -4.17%
association presentation cancer cell research meeting skin trial results
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
MDT | $80.23 0.13% 0.2% 6.9M
|
Health Technology
| Email alert
Add to watchlist
EW M | $89.2 -1.2% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
treatment for women smart trial platform
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials
Published: 2024-04-05 (Crawled : 14:30) - biospace.com/
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -1.84%
H: 0.0%
C: 0.0%
neuroinflammatory back trials
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | $90.42 -4.29% -4.48% 1.2M
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
Published: 2024-04-04 (Crawled : 23:00) - biospace.com/
DTIL | $13.02 -7.79% -8.45% 110K
|
Health Technology
|
| O: -2.33%
H: 1.64%
C: -4.91%
ecur-506 fda drug treatment clearance for application trial
Berger Montague Announces that its False Claims Act Whistleblower Case Against CVS Health Will Move Forward to Trial
Published: 2024-04-04 (Crawled : 23:00) - prnewswire.com
LUNA | $2.42 -6.92% -7.44% 1M
|
Electronic Technology
|
| O: -4.29%
H: 2.07%
C: 0.69%
health trial
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
Published: 2024-04-04 (Crawled : 19:00) - biospace.com/
HALB | $0.008 7.14% 190K
|
n/a
|
| O: 3.49%
H: 7.23%
C: 1.2%
contract research trial
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.91 -8.17% -8.9% 410K
|
|
| O: -76.55%
H: 13.89%
C: -17.78%
lung cancer cell topline trial therapeutics results
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
TPST | $3.33 -7.24% -7.81% 590K
|
Manufacturing
|
| O: 8.39%
H: 2.71%
C: -12.96%
tpst-1120 tumors positive cancer publication research communications trial advanced
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6108 -8.97% -9.86% 450K
|
Health Care and Social Assistan...
|
| O: 1.34%
H: 0.0%
C: -4.21%
bt-600 positive trial therapeutics results platform
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.835 -12.39% -14.14% 2.2M
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $126.19 0.36% 0.15% 6.2M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
ADCT | $4.37 -0.46% 0.0% 460K
|
Health Technology
|
| O: 0.68%
H: 11.71%
C: 6.08%
zynlonta trial therapeutics
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.